Sign up to save your podcasts
Or
Share 30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 16 Label Accuracy in Psychedelic Products
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 16 Label Accuracy in Psychedelic Products
This podcast episode explores the critical importance of label accuracy in psilocybin products, drawing parallels to early challenges in the cannabis industry. The discussion covers key topics including:
- The use of advanced testing methods like LCMS (liquid chromatography mass spectrometry) to accurately measure psilocybin and psilocin levels
- Current challenges in the unregulated market, described as a "Wild West" environment with varying product quality and potency
- The FDA's emerging role in regulation through PDUFA guidelines
- Special considerations for different product forms, including dried mushrooms, extracts, and microdosing products
The episode emphasizes how accurate labeling is fundamental to consumer safety, market trust, and the responsible development of the psychedelic industry.
View all episodes
By Jim Mitchell and Google NotebookLMThis podcast episode explores the critical importance of label accuracy in psilocybin products, drawing parallels to early challenges in the cannabis industry. The discussion covers key topics including:
- The use of advanced testing methods like LCMS (liquid chromatography mass spectrometry) to accurately measure psilocybin and psilocin levels
- Current challenges in the unregulated market, described as a "Wild West" environment with varying product quality and potency
- The FDA's emerging role in regulation through PDUFA guidelines
- Special considerations for different product forms, including dried mushrooms, extracts, and microdosing products
The episode emphasizes how accurate labeling is fundamental to consumer safety, market trust, and the responsible development of the psychedelic industry.